Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD)
Stefano Cascinu(Vita-Salute San Raffaele University), Rodolfo Passalacqua(Champalimaud Foundation), Davide Pastorelli, Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Emiliano Tamburini(Ospedale Infermi di Rimini), L. Ciuffreda(Azienda Ospedaliero Universitaria San Giovanni Battista), G. Aprile, Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Kumari Chandrawansa(SUNY Upstate Medical University), Charles S. Fuchs(University of Southern California), H. Wilke(Kliniken Essen-Mitte), Gabriella Farina(ASST Fatebenefratelli Sacco), Giordano Beretta(Humanitas Gavazzeni), Vito Amoroso(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Angela Buonadonna(Centro di Riferimento Oncologico), Nicola Silvestris(University of Messina), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), D. Amoroso(Ospedale Versilia), Alberto F. Sobrero(Ospedale Policlinico San Martino), Donata Sartori(Ospedale di Mirano), Yanzhi Hsu(CDG Therapeutics (United States)), Roberto Bordonaro(Ospedale Garibaldi)
Cited by 0
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
|JAMA Oncology|2018|1.8k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k